Search PubMed⌕ Search

Biomedical subjects

F Pisani

Publications and source records attributed to F Pisani.

At least 145 records · Page 8Linked to original sources
PubMed1983

[Minor anal pathology. Suggestions for ambulatory and hospital treatment].

A series of cases of anorectal pathology treated at the out-patient level or after hospitalisation in the course of the last five years is reviewed. Deference is made to subjects with haemorrhoids operated according to Milligan-Morgan or Parks in accordance with varying indications, or treated cryosurgically as out-patients, patients with upper or lower transsphincteric perianal fistula treated by means of the lay-open technique or elastic tourniquet under general or local anaesthesia, patients with acute anal fissures treated by means of internal lateral sphincterotomy under local anaesthesia, and those with inveterate forms subjected to Arnous posterior leiomyotomy. From a critical assessment of the hospital and out-patient activities carried out suggestions and indications are drawn with regard to cases that must be treated in hospital and those for which outpatient management is correct.

Ambulatory Care↗
PubMed1983

[Cryogenic treatment of rectal tumors].

10 patients with anal or rectal cancers were given liquid nitrogen cryogenic treatment. In 5 cases the treatment was given prior to abdominoperineal amputation of the rectum. The remaining 5 inoperable cases were given the cryogenic treatment alone, followed, in 3 cases by derivative colostomy. Histological reports on the removed tissues, carried out at different times after the cryogenic treatment, showed the effects of the treatment on the neoplasias and the surrounding tissues and showed the histological equivalent of possible local immunological processes. The thrombosis in the surrounding blood vessels appears to indicate the efficacity of cryogenic therapy in preventing the metastasis of neoplastic cells.

Adenocarcinoma↗
PubMed1983

Intra-daily oscillations in dipropylacetic acid plasma levels with two or three daily doses of dipropylacetamide in epileptic patients.

The diurnal fluctuations in dipropylacetic acid (DPA) plasma levels were examined in ten epileptic patients following a chronic treatment with 3 or 2 daily doses of dipropylacetamide (DPM). The highest/lowest DPA levels ratios observed throughout 24 hrs were 1.18 and 1.36, respectively, but the difference in the data was not statistically significant (p greater than 0.05). The present results indicate that a reduction of the frequency of the daily administrations of the drug can be made with consequent possible improvement in the patient's compliance. The clinical value of the oscillations in DPA serum levels is also revised in the light of the data reported in the literature.

Adolescent↗
PubMed1982

Increased dipropylacetic acid bioavailability from dipropylacetamide by food.

The present study was designed to investigate the influence of food on dipropylacetic acid (DPA) absorption from dipropylacetamide (DPM). Six healthy male volunteers received at weekly intervals, in a crossover randomized fashion, a single oral dose of 60 mg DPM, as 2 X 300-mg capsules, in a fasting state and after a standard meal. In the latter state, the lag time of DPA appearance in the serum increased significantly (p less than 0.02) from 0.6 +/- 0.2 to 2.3 +/- 1.2 h (mean values +/- SD). Maximal DPA serum levels and bioavailability increased significantly (p less than 0.05), with mean values of 27.7 +/- 19.8 and 19.0 +/- 14.7%, respectively, following food. The slower gastric emptying with a consequent improved DPM exposure to metabolizing enzymes and changes in gastric pH probably accounted for these findings. These results suggest that it is more advantageous to take DPM after meals. This helps to reduce gastrointestinal disturbances and to promote DPA absorption.

Absorption↗
PubMed1982

Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs.

The pharmacokinetics of phenylethylmalonamide (PEMA), a major metabolite of primidone, were investigated following administration of single oral doses (400 mg) to six normal subjects and six patients receiving chronic treatment with antiepileptic drugs. Peak serum PEMA levels were usually attained with 2-4 h after intake. The oral bioavailability estimated on the basis of the recovery of unchanged drug in the urine of normal subjects was at least 80%. Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients. No statistically significant difference in any of the calculated kinetic parameters could be found between the two groups. The data indicate that PEMA is readily absorbed from the gastrointestinal tract and that it is eliminated predominantly unchanged in the urine of man.

Adult↗
PubMed1981

Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide.

Diurnal variation in dipropylacetic acid (DPA) plasma levels was investigated in 47 and 42 epileptic patients, chronically treated with sodium dipropylacetate and dipropylacetamide (DPM), respectively, taken alone or in addition to other antiepilepic drugs. Fluctuation in DPA plasma levels was significantly less in patients receiving dipropylacetamide. The slow absorption and the more prolonged plasma half-life of dipropylacetamide accounted for these findings. Although the importance of diurnal fluctuations in DPA levels has not yet been established, possible clinical implications are discussed.

Adolescent↗
PubMed1981

Phenylethylmalonamide in essential tremor. A double-blind controlled study.

A randomised double-blind placebo-controlled trial of phenylethylmalonamide, the major metabolite of primidone was performed in eight patients with essential tremor. Phenylethylmalonamide was given in a daily dose of 400 mg for one week and 800 mg for a second week. The compound had no statistically significant effect on the amplitude of tremor assessed by an accelerometric method, tests of performance, clinical evaluation and patient self assessment. No side effects occurred. Serum levels of phenylethylmalonamide on a daily dose of 400 mg were 11-27 micrograms/ml and on 800 mg daily were 16-48.5 micrograms/ml.

Adult↗
PubMed1980

Preliminary data on dipropylacetamide absorption in rats.

Absorption of dipropylacetamide, after oral and i.m. administration, was studied in different groups of male albino Wistar rats. After i.m. administration, only unmodified amide was found in plasma, whereas oral administration of the drug was followed by the presence of dipropylacetic acid and dipropylacetamide in plasma. This last compound resulted in a higher amount in a further group of rats previously treated with neomycin in order to avoid the action of intestinal flora. Present results seem to exclude an hepatic role in the transformation of dipropylacetamide in dipropylacetic acid.

Absorption↗
PubMed1980

Some clinical pharmacological aspects of n-dipropylacetamide.

The kinetics of the primary amide of valproic acid (VPA), i.e. dipropylacetamide, rapidly transformed into the corresponding acid in humans, are investigated and compared with valproate kinetics. In a group of healthy volunteers peak VPA concentration was reached within 5-14 hours of dipropylacetamide and within 1-2 hours of valproate administration. The plasma half-life appeared to be 8-12 hours for both compounds without significant differences. The relative bioavailability of the amide was 81.2% of valproate on average. In epileptics no correlation between plasma VPA levels and daily valproate or amide dose was observed; daily plasma valproic acid level fluctuations were significantly less wide during dipropylacetamide therapy. This compound seems to offer some advantages over sodium valproate, namely: slower absorption, stabler plasma levels through the day, 2 instead of 3 or 4 daily doses and hence less risk of drug defaulting.

Adult↗